Literature DB >> 22228496

Serum sphingolipids and inflammatory mediators in adolescents at risk for metabolic syndrome.

I Majumdar1, L D Mastrandrea.   

Abstract

The purpose of this study was to determine low-grade inflammation associated with obesity that is mediated partially by TNF-α, an adipocytokine which stimulates sphingomyelinase activity in adipocytes. Circulating ceramide (Cer) and sphingosine 1-phosphate (S1P) are elevated in genetically obese (ob/ob) mice. We aimed to determine whether serum sphingolipid concentrations correlate with measures of obesity, insulin resistance, and lipid profiles in overweight versus lean adolescents. This cross-sectional study recruited 30 healthy overweight (body mass index, BMI ≥ 85%) and 15 lean (BMI 10-84%) adolescents. Anthropometric measurements and fasting blood samples were collected at one clinic visit. Serum glucose, insulin, and fasting lipid profiles were measured. Serum adipocytokine concentrations were measured by ELISA or colorimetric assay and sphingolipids were measured by HPLC-mass spectrometry. Between group differences in serum sphingolipid concentrations were assessed. Correlations between sphingolipid concentrations and (i) body mass index, (ii) calculated homeostasis model assessment of insulin resistance (HOMA-IR), (iii) adipocytokines, and (iv) lipoproteins were determined. The results showed that significant differences in HOMA-IR (4.5 ± 3.2 vs. 1.2 ± 0.7), free fatty acids (0.8 ± 0.3 mmol/l vs. 0.4 ± 0.3 mmol/l), and adiponectin (6.4 ± 3.8 vs. 12.6 ± 9.9 μg/ml) were seen between groups (overweight vs. lean). There were significant correlations between Cer and TNF-α (r = 0.429), S1P and TNF-α (r = 0.288), Cer and adiponectin (r = 0.321), Cer:S1P and adiponectin (r = 0.324), Cer and HOMA-IR (r = 0.307), and Cer:S1P and LDL cholesterol (r = 0.453); these associations persisted after adjustment for BMI Z-score, sex, and Tanner stage. We concluded that elevated sphingolipid concentrations correlate with TNF-α, adiponectin, lipoprotein profiles, and HOMA-IR. Ceramide is associated with atherogenic lipid profiles and the development of insulin resistance in obese adolescents, similar to adults.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228496     DOI: 10.1007/s12020-011-9589-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  31 in total

1.  Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk.

Authors:  Fahumiya Samad; Kelly D Hester; Guang Yang; Yusuf A Hannun; Jacek Bielawski
Journal:  Diabetes       Date:  2006-09       Impact factor: 9.461

2.  Ceramide concentrations in septic patients: a possible marker of multiple organ dysfunction syndrome.

Authors:  G Delogu; G Famularo; F Amati; L Signore; A Antonucci; V Trinchieri; L Di Marzio; M G Cifone
Journal:  Crit Care Med       Date:  1999-11       Impact factor: 7.598

3.  Activation of the sphingosine kinase-signaling pathway by high glucose mediates the proinflammatory phenotype of endothelial cells.

Authors:  Lijun Wang; Xiao-Ping Xing; Andrew Holmes; Carol Wadham; Jennifer R Gamble; Mathew A Vadas; Pu Xia
Journal:  Circ Res       Date:  2005-09-22       Impact factor: 17.367

4.  Gastric bypass surgery reduces plasma ceramide subspecies and improves insulin sensitivity in severely obese patients.

Authors:  Hazel Huang; Takhar Kasumov; Patrick Gatmaitan; Helen M Heneghan; Sangeeta R Kashyap; Philip R Schauer; Stacy A Brethauer; John P Kirwan
Journal:  Obesity (Silver Spring)       Date:  2011-05-05       Impact factor: 5.002

5.  Ceramide metabolism is affected by obesity and diabetes in human adipose tissue.

Authors:  A U Błachnio-Zabielska; M Pułka; M Baranowski; A Nikołajuk; P Zabielski; M Górska; J Górski
Journal:  J Cell Physiol       Date:  2012-02       Impact factor: 6.384

6.  Recent trends in waist circumference and waist-height ratio among US children and adolescents.

Authors:  Chaoyang Li; Earl S Ford; Ali H Mokdad; Stephen Cook
Journal:  Pediatrics       Date:  2006-11       Impact factor: 7.124

7.  Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999-2002.

Authors:  Stephen Cook; Peggy Auinger; Chaoyang Li; Earl S Ford
Journal:  J Pediatr       Date:  2007-10-22       Impact factor: 4.406

8.  Blood pressure nomograms for children and adolescents, by height, sex, and age, in the United States.

Authors:  B Rosner; R J Prineas; J M Loggie; S R Daniels
Journal:  J Pediatr       Date:  1993-12       Impact factor: 4.406

Review 9.  Obesity, metabolic syndrome, and cardiovascular disease.

Authors:  Yacine Aggoun
Journal:  Pediatr Res       Date:  2007-06       Impact factor: 3.756

Review 10.  Sphingosine-1-phosphate in cell growth and cell death.

Authors:  S Spiegel; O Cuvillier; L C Edsall; T Kohama; R Menzeleev; Z Olah; A Olivera; G Pirianov; D M Thomas; Z Tu; J R Van Brocklyn; F Wang
Journal:  Ann N Y Acad Sci       Date:  1998-06-19       Impact factor: 5.691

View more
  28 in total

1.  Increased serum concentration of sphingosine-1-phosphate in juvenile-onset systemic lupus erythematosus.

Authors:  L Watson; K Tullus; S D Marks; R C L Holt; C Pilkington; M W Beresford
Journal:  J Clin Immunol       Date:  2012-05-31       Impact factor: 8.317

Review 2.  Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.

Authors:  Jan-Bernd Funcke; Philipp E Scherer
Journal:  J Lipid Res       Date:  2019-06-17       Impact factor: 5.922

Review 3.  Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors.

Authors:  K Alexa Orr Gandy; Lina M Obeid
Journal:  Biochim Biophys Acta       Date:  2012-07-16

4.  The association of obesity with hearing thresholds in women aged 18-40 years.

Authors:  Rıfkı Üçler; Mahfuz Turan; Fatih Garça; İsmail Acar; Murat Atmaca; Hakan Çankaya
Journal:  Endocrine       Date:  2015-10-01       Impact factor: 3.633

Review 5.  Lipid deposition and metaflammation in diabetic kidney disease.

Authors:  Alla Mitrofanova; Antonio M Fontanella; Sandra Merscher; Alessia Fornoni
Journal:  Curr Opin Pharmacol       Date:  2020-11-01       Impact factor: 5.547

Review 6.  Sphingolipids and phospholipids in insulin resistance and related metabolic disorders.

Authors:  Peter J Meikle; Scott A Summers
Journal:  Nat Rev Endocrinol       Date:  2016-10-21       Impact factor: 43.330

Review 7.  Sphingolipid metabolites in inflammatory disease.

Authors:  Michael Maceyka; Sarah Spiegel
Journal:  Nature       Date:  2014-06-05       Impact factor: 49.962

8.  Hematological parameters are associated with metabolic syndrome in Japanese community-dwelling persons.

Authors:  Ryuichi Kawamoto; Yasuharu Tabara; Katsuhiko Kohara; Tetsuro Miki; Tomo Kusunoki; Masanori Abe; Tateaki Katoh
Journal:  Endocrine       Date:  2013-01-10       Impact factor: 3.633

9.  Recombinant murine fibroblast growth factor 21 ameliorates obesity-related inflammation in monosodium glutamate-induced obesity rats.

Authors:  Wen-Fei Wang; Si-Ming Li; Gui-Ping Ren; Wei Zheng; Yu-Jia Lu; Yin-Hang Yu; Wen-Juan Xu; Tian-He Li; Li-Hong Zhou; Yan Liu; De-Shan Li
Journal:  Endocrine       Date:  2014-10-12       Impact factor: 3.633

10.  Maternal obesity leads to long-term altered levels of plasma ceramides in the offspring as revealed by a longitudinal lipidomic study in children.

Authors:  Luis Felipe León-Aguilar; Mikael Croyal; Véronique Ferchaud-Roucher; Fengyang Huang; Laurence A Marchat; Albino Barraza-Villarreal; Isabelle Romieu; Usha Ramakrishnan; Michel Krempf; Khadija Ouguerram; Rosalio Mercado-Camargo; Francisco Bolaños-Jiménez
Journal:  Int J Obes (Lond)       Date:  2018-12-19       Impact factor: 5.095

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.